SC-12 · Supportive Compound
Supportive compoundSynthetic demo dataTarget state: Tolerance deterioration · onset 6 d · prior: symptom −18%, persistence +11%, tolerance +18%Simulate for P-01454
For P-01454
Eligible at 75% confidence. Among the 284 most similar trajectories: 46 accepted, 65% improved, mean effect −14%.
What it is
A fictional supportive compound taken twice daily for 21 days to blunt the mucosal toxicity of the asset, with pharmacist counselling and a weekly lab check.
How it works
Mucosal cytoprotection and reduced local inflammatory signalling (demo mechanism). Acts on toxicity first; GI burden follows with a lag.
What the patient does, day by day
| Day 1 | 🏥 | Pharmacist counselling Interaction check, dose timing relative to the asset, what to expect. |
| Every day | 💊 | SC-12 twice daily Morning and evening with food; reminder in the companion. |
| Weekly | 🏥 | Lab check Liver panel and CBC (demo). |
| Every evening | ✓ | Symptom check-in GI and fatigue scores. |
| Day 21 | 🏥 | Outcome read Toxicity and GI vs prediction. |
Delivery
- Owner
- Pharmacist
- Channel
- Dispensed at site; adherence tracked in the companion
- Duration
- 21 days
- Touchpoints
- Twice daily dose reminder; weekly pharmacist call
- Cost
- ≈ €420 per patient (compound + labs)
Monitoring
- · Weekly labs
- · Daily GI and fatigue
- · Adherence to SC-12
Stop rules
- · Lab abnormality grade ≥ 2 → stop, investigator
- · No toxicity change by day 14 → stop, re-plan
Contraindications
- · DPYD variant (interaction flag)
- · Hepatic impairment
- · Concurrent CYP2D6 strong inhibitors
Evidence in NBL-101
48 accepted · 65% improved · mean effect −14%By biology segment
| Poor metabolizer | n 4 | 75% |
| Baseline state S14 | n 31 | 74% |
| IL6 high-expression variant | n 31 | 68% |
| Low butyrate capacity | n 31 | 68% |
| Low microbial diversity | n 42 | 67% |
| Cluster EC-03 (high response / high intolerance) | n 45 | 67% |
| Adherence < 60% | n 43 | 65% |
| FUT2 non-secretor | n 31 | 61% |
By trajectory cluster
| EC-03 | n 45 | 67% |
Works best when
- · Toxicity-led deterioration (tox rising before GI)
- · Poor metabolizers
- · Low butyrate capacity
Works poorly when
- · Diet-driven GI patterns (fat / histamine detractors)
- · Cluster EC-03 without concurrent GI protocol
What the model has learned about it
No learned rule yet for SC-12. Run learning after campaign results.
Campaigns using it
None yet. 232 patients look eligible right now.